Friday, November 15, 2013 - 08:00

 

  • MICA validated as a novel target for antibody drug development in solid tumors
  • IPH43 program now aims at selection and optimization of the best development candidate

 

Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH), the innate immunity company developing first-in-class drug candidates for cancer and inflammatory diseases, announces the initiation of a new program to develop an anti-MICA therapeutic antibody in oncology. The program, named IPH43, is the newest to emerge from Innate Pharma’s discovery platform.

MICA is a highly polymorphic ligand of the NK cell activating receptor NKG2D. MICA is specifically expressed on several highly prevalent solid tumors including breast, colorectal and lung. Innate Pharma has generated a panel of high affinity antibodies recognizing all forms of MICA which is now being tested and optimized to select the best development candidate.

AttachmentSize
PR in English74.11 KB
CP en français74.86 KB
Poster on IPH43 presented at SITC 2013489.35 KB